Free

Two years before the role of EGFR mutations was understood, ODAC recommended accelerated approval of Iressa for NSCLC
FreeIn the Archives

Two years before the role of EGFR mutations was understood, ODAC recommended accelerated approval of Iressa for NSCLC

On Sept. 24, 2002, the Oncologic Drugs Advisory Committee recommended an accelerated approval for AstraZeneca’s Iressa (gefitinib). The recommendation concluded a meeting where ODAC weighed whether the drug, an EGFR tyrosine kinase inhibitor, could benefit patients with resistant or refractory non-small cell lung cancer as a third-line therapy.
ACS, ASCO combine online patient information services
Conversation with The Cancer LetterFree

ACS, ASCO combine online patient information services

The American Cancer Society and the American Society of Clinical Oncology have combined their cancer information resources, which will be available at no cost to the public on cancer.org. The collaboration, which combines the two organizations’ sites—ACS’s cancer.org and ASCO’s cancer.net—was announced at the 2024 ASCO Annual Meeting in Chicago May 1. Cancer.org is now […]